The Inflation Reduction Act (IRA) takes important steps to reduce drug prices and lower costs for people with Medicare and the program, such as capping beneficiary out-of-pocket spending; requiring Medicare to negotiate drug prices; and expanding eligibility for the full Part D low-income subsidy (LIS). We support an implementation process that centers the beneficiary experience and look forward to building upon these landmark policies.
Last week, CMS released additional guidance regarding Medicare Prescription Payment Plan (MPPP) outreach and education. The MPPP, sometimes referred to
The Inflation Reduction Act (IRA) of 2022 made key changes in Medicare law and coverage to improve prescription drug affordability for older adults and people with disabilities. Since its passage, some stakeholders and lawmakers have targeted IRA policies for revision or repeal, especially the law’s Medicare Drug Price Negotiation Program. Depending on the provisions targeted, this would increase beneficiary costs and increase Medicare spending.
Prior authorization is one of the processes Medicare Advantage and other private insurance companies use to manage health care utilization
Earlier this month, the U.S. Department of Health and Human Services Office of the Assistant Secretary for Planning and Evaluation
Earlier this month, the U.S. Department of Health and Human Services Office of the Assistant Secretary for Planning and Evaluation
A new study from University of Southern California (USC) researchers shows that Medicare Part D plans have been increasingly restricting
Many people with Medicare Part D drug coverage—in particular those who reach the catastrophic coverage phase—may experience unexpected costs and
KFF has released a new issue brief previewing expected savings for millions of Medicare Part D enrollees starting in 2025
On February 1, the U.S. Department of Health and Human Services (HHS) sent initial offers to manufacturers of the first
Last week, CMS released additional guidance regarding Medicare Prescription Payment Plan (MPPP) outreach and education. The MPPP, sometimes referred to
The Inflation Reduction Act (IRA) of 2022 made key changes in Medicare law and coverage to improve prescription drug affordability for older adults and people with disabilities. Since its passage, some stakeholders and lawmakers have targeted IRA policies for revision or repeal, especially the law’s Medicare Drug Price Negotiation Program. Depending on the provisions targeted, this would increase beneficiary costs and increase Medicare spending.
Prior authorization is one of the processes Medicare Advantage and other private insurance companies use to manage health care utilization
Earlier this month, the U.S. Department of Health and Human Services Office of the Assistant Secretary for Planning and Evaluation
Earlier this month, the U.S. Department of Health and Human Services Office of the Assistant Secretary for Planning and Evaluation
A new study from University of Southern California (USC) researchers shows that Medicare Part D plans have been increasingly restricting
Many people with Medicare Part D drug coverage—in particular those who reach the catastrophic coverage phase—may experience unexpected costs and
KFF has released a new issue brief previewing expected savings for millions of Medicare Part D enrollees starting in 2025
On February 1, the U.S. Department of Health and Human Services (HHS) sent initial offers to manufacturers of the first
